Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the overall safety and effectiveness of an
investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one
that has not been approved by the FDA. Approximately 40 people will be enrolled on this study
at the University of Pennsylvania (Main Institution/Coordinating Site) and the University of
Chicago (Participating Institution). We expect about 20 subjects to be enrolled at each
institution.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania